A phase I and pharmacologic study of the proteosome inhibitor PS-341 [bortezomib] in patients with advanced solid tumors and B-cell lymphoproliferative disorders
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2011
At a glance
- Drugs Bortezomib (Primary)
- Indications B cell lymphoma; Leukaemia; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2005 New trial record.